Overview: NGS Hypokalemic Paralysis Sequencing TestIntroduction: The NGS Hypokalemic Paralysis Sequencing Test sequences genes to diagnose hypokalemic periodic paralysis, causing muscle weakness. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected hypokalemic periodic paralysis (HPP).
Other Names: HPP NGS Assay, CACNA1S/SCN4A Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: HPP sequencing began in the 1990s with ion channel disorder research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose hypokalemic periodic paralysis, guides treatment, and evaluates patients with muscle weakness.
Test Parameters: 1. Hypokalemic Paralysis Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of muscle weakness, paralysis episodes, or HPP symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document muscle weakness, paralysis episodes, low potassium levels, or family history of HPP. Include current medications, especially potassium supplements.
Consent: Written consent required, detailing the tests purpose, HPP implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze HPP genes (e.g., CACNA1S, SCN4A). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for HPP diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm HPP, guiding potassium supplementation or acetazolamide therapy. Negative results may require electrolyte testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Serum potassium levels, EMG, or muscle biopsy to confirm HPP diagnosis.
Test Limitations: Not all HPP cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN HPP Guidelines, 2023; Neurology, Statland JM, 2022.
